tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Gyre Therapeutics Launches $20 Million Public Stock Offering

Story Highlights
Gyre Therapeutics Launches $20 Million Public Stock Offering

Elevate Your Investing Strategy:

GNI Group ( (JP:2160) ) just unveiled an update.

Gyre Therapeutics, a subsidiary of GNI Group Ltd., has announced a public offering of its common stock, aiming to raise approximately $20 million. The proceeds will support the Phase 2 clinical trial of F351 in the U.S. and other corporate purposes, with a potential dilution rate of 2.83% for existing shareholders.

The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

More about GNI Group

GNI Group Ltd. operates in the pharmaceutical industry, focusing on innovative drug development and therapeutic solutions. Its core subsidiary, Gyre Therapeutics, is involved in advancing clinical trials and research, particularly targeting liver fibrosis caused by metabolic dysfunction-associated steatohepatitis (MASH).

Average Trading Volume: 2,353,867

Technical Sentiment Signal: Hold

Current Market Cap: Yen124.8B

See more data about 2160 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1